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Abstract
Objective— The cytochromes P450 epoxygenases CYP2J2 and CYP2C8 synthesize
epoxyeicosatrienoic acids, which regulate endothelial function. We sought to determine if genetic
variation in CYP2J2 and CYP2C8 was associated with coronary heart disease risk.
Methods— We genotyped 2065 Atherosclerosis Risk in Communities study participants (1085
incident coronary heart disease cases, 980 noncases) for polymorphisms in CYP2J2 and CYP2C8.
Using a case–cohort design, associations between genotype and incident coronary heart disease risk
were evaluated using proportional hazards regression. The influence of cigarette smoking on these
associations was also evaluated. False discovery rate q-values were estimated to minimize the impact
of the multiple statistical comparisons completed. All analyses were race stratified.
Results— The CYP2J2 G-50T polymorphism variant –50T allele was associated with significantly
lower risk of incident coronary heart disease in African-Americans (adjusted hazard rate ratio 0.58,
95% confidence interval 0.35–0.96, P = 0.036, q = 0.051); however, no significant association was
observed in Caucasians. Overall, the I264M, I269F, and K399R polymorphisms in CYP2C8 were
not significantly associated with risk of incident coronary heart disease. In Caucasians, the
relationship between the I264M and K399R polymorphisms and incident coronary heart disease risk
was significantly modified by cigarette smoking status (P for interaction = 0.008, q = 0.064), with
the highest risk observed in smokers carrying at least one variant allele.
Conclusions— The G-50T polymorphism in CYP2J2 may be an important risk factor for the
development of coronary heart disease events in African-Americans, whereas cigarette smoking may
modify the relationship between the I264M and K399R polymorphisms in CYP2C8 and coronary
heart disease risk in Caucasians. Confirmation of these findings in an independent population is
warranted.
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Introduction
Coronary heart disease (CHD) is a major cause of morbidity and mortality, with 1.2 million
Americans estimated to experience a new or recurrent acute coronary syndrome event this year
[1]. Endothelial dysfunction is associated with risk of CHD events such as myocardial
infarction [2]. Various risk factors including cigarette smoking contribute to this process [3],
which has been primarily ascribed to functional impairments in nitric oxide biosynthesis and
activity. However, dysfunction, in other endothelial pathways also appears to be important.
Arachidonic acid is oxidatively metabolized to epoxyeicosatrienoic acids (EETs) in endothelial
cells and cardiomyocytes by the cytochromes P450 epoxygenases CYP2J2 and CYP2C8 [4].
The EETs have potent vasodilatory [5,6], antiinflammatory [7], fibrinolytic [8], and
postischemic cardioprotective [9,10] effects, and are considered one of the primary endothelial-
derived hyperpolarizing factors [5,6]. Multiple genetic polymorphisms in CYP2J2 and
CYP2C8 have been recently discovered [11–14]. In CYP2J2, the G-50T (CYP2J2*7)
polymorphism in the proximal promoter disrupts a Sp1 transcription factor binding site and
leads to reduced CYP2J2 transcription [12]. In CYP2C8, the I269F (CYP2C8*2), R139K/
K399R (CYP2C8*3) and I264M (CYP2C8*4) nonsynonymous variants possess lower CYP2C8
metabolic activity in vitro [13,14]. Case–control studies have demonstrated an association
between the CYP2J2 – 50T variant allele and higher risk of angiographically documented CHD
in a German population [12], and between the CYP2C8*3 variant allele and higher risk of
prevalent myocardial infarction in a Swedish cohort [15]. Associations between
polymorphisms in these genes and risk of incident CHD clinical events, however, remain to
be evaluated.
Our primary aim was to determine if genetic variation in CYP2J2 and CYP2C8 was associated
with risk of incident CHD events in individuals enrolled in the biethnic Atherosclerosis Risk
in Communities (ARIC) study. A secondary aim was to determine if this risk was modified by
environmental factors known to impair endothelial function such as cigarette smoking.
Methods
Study population
Participants were selected from the ARIC study, a longitudinal, population-based cohort study
of 15 792 men and women aged 45–64 years from four U.S. communities (Forsyth County,
North Carolina; Jackson, Mississippi; Minneapolis, Minnesota; and Washington County,
Maryland) enrolled between 1987 and 1989 [16]. Since enrollment, participants have been
followed prospectively via annual phone interviews, clinic examinations approximately every
3 years through 1998, and ongoing abstraction of hospital and death certificate records. The
study protocol was approved by the Institutional Review Board of each center, and consent
was obtained from each participant.
Ascertainment of incident coronary heart disease cases
All incident cases that occurred between baseline and 31 December 1998 were evaluated
(median follow-up 9.1 years), excluding participants with a history of a physician-diagnosed
CHD or stroke event at baseline. Incident CHD (n = 1085) was defined as (1) definite or
probable myocardial infarction (n = 520), (2) electrocardiographic evidence of silent
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myocardial infarction (n = 112), (3) definite CHD death (n = 1 10), or (4) coronary
revascularization procedure (n = 343). The ascertainment of cases and criteria for classification
have been described previously [17]. All potential events were systematically reviewed and
adjudicated by the ARIC Morbidity and Mortality Classification Committee [16,17]. Briefly,
hospitalized myocardial infarction was classified as definite or probable based on chest pain
symptoms, cardiac enzyme levels, and electrocardiographic changes. An unrecognized or silent
myocardial infarction was defined by presence of a major Q-wave, a minor Q-wave with
ischemic ST-Tchanges or evidence of a myocardial infarction by computerized Novacode
criteria [18] via a 12-lead electrocardiogram obtained during an ARIC follow-up examination.
Presence of a new finding was confirmed by visual comparison of the baseline and follow-up
electrocardiograms by a centralized reader. Definite CHD death was classified based on chest
pain symptoms, underlying cause of death, hospitalization records, and medical history.
Coronary revascularization procedures included coronary artery bypass grafting and
percutaneous coronary interventions.
Baseline measurements
Detailed demographic, clinical, and biochemical data were obtained from each participant at
baseline, as described [19,20]. Briefly, race was self-reported and detailed information on
cigarette smoking was obtained through an interview-administered questionnaire.
Cohort random sample
A random sample of all ARIC participants without history of CHD or stroke at baseline was
assembled to serve as the reference group for the case–cohort comparisons (n = 1065, 85 of
which are also incident CHD cases). Sampling of the cohort was stratified on age (<55 or ≥ 55
years), sex, and race (Caucasian or African-American). Sampling proportions varied across
each stratum.
Genotyping
Genomic DNA from all incident CHD cases and the cohort random sample was genotyped for
10 polymorphisms in coding and noncoding regions of CYP2J2 (Fig. 1) and the
nonsynonymous I269F (CYP2C8*2), K399R (CYP2C8*3), and I264M (CYP2C8*4)
polymorphisms in CYP2C8 using either multiplex matrix-assisted laser desorption/ionization
time-of-flight mass spectrometry (Sequenom Inc., San Diego, California) [21] or BeadArray
(Illumina Inc., San Diego, California) [22] methods, as described (Supplementary Table 1
available online). Blind replicates were included for quality control.
The CYP2J2 polymorphisms were identified from our resequencing effort as part of the NIEHS
Environmental Genome Single Nucleotide Polymorphism program (https://dir-
apps.niehs.nih.gov/egsnp/home.htm) [11] and specifically selected based on their known
functional relevance in vitro and/or haplotype tagging properties. Owing to the very low
frequency of nonsynonymous variants in CYP2J2, evaluation of potential associations between
common CYP2J2 haplotypes and CHD risk were also considered. Briefly, pairwise linkage
disequilibrium (LD) statistics were calculated and haplotypes were reconstructed separately in
European/Caucasians (n = 24) and Africans (n = 24) using all polymorphisms in CYP2J2
identified by resequencing (Haploview 3.2) [11,23]. Polymorphisms tagging haplotypes with
>5% frequency in either population were selected for genotyping.
Three nonsynonymous polymorphisms in CYP2C8 (CYP2C8*2, *3 and *4) were selected since
these represent the most frequent variants in Caucasian or African-American populations with
known functional relevance [13,14]. The CYP2C8*3 variant consists of two nonsynonymous
polymorphisms in perfect LD (R139K and K399R) [13]; however, only the K399R locus was
genotyped in our analysis. CYP2C8 haplotype tagging polymorphisms were not evaluated.
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All incident CHD cases and individuals from the cohort random sample were included in our
analysis (n = 2065). Inverse sampling fractions from each stratum were used as weights in
estimation of adjusted covariate means and proportions by linear and logistic regression,
respectively, in noncases included in the cohort random sample. Hazard rate ratios (HRR) and
95% confidence intervals (CI) for the development of incident CHD in relation to CYP2J2 or
CYP2C8 genotype were calculated by weighted proportional hazards regression, using
Barlow’s method to account for the stratified random sampling and case–cohort design [24].
Model 1 included baseline age, sex, and study center as covariates. Model 2 also included
current smoking status, diabetes, hypertension, high-density lipoprotein cholesterol, total
cholesterol, and body mass index at baseline. Assuming an autosomal-dominant mode of
inheritance, individuals with one or two variant alleles were combined for comparison with
wild-type individuals. This assumption was based on previous studies demonstrating
significant functional effects of CYP2J2 and CYP2C8 polymorphisms in individuals carrying
one or two variant alleles [12,14]. All analyses were completed separately in Caucasians and
African-Americans. Assuming a case–control design, type I error α = 0.05 and 10% variant
genotype frequency, we had approximately 99 and 80% power to detect an odds ratio of 2.0
in Caucasians and African-Americans, respectively.
Cohort random sample allele frequencies were evaluated for deviation from Hardy–Weinberg
equilibrium, separately in Caucasians and African-Americans, and pairwise LD statistics were
calculated (Haploview 3.2) [23]. CYP2J2 haplotypes and their frequencies were estimated
using the phase reconstruction method (PHASE 2.1), which assigned the most probable
haplotype pair to each individual [25]. Only polymorphisms with >5% frequency and pairwise
r2 values <0.80 were considered for haplotype reconstruction, which included polymorphisms
1 and 7 in Caucasians and 1, 7, 9, and 10 in African-Americans (Fig. 1). Haplotype frequencies
were compared across case status by χ2. Only haplotypes with >5% frequency were considered.
Frequency comparisons were repeated using the expectation–maximization algorithm
(Haploview 3.2) [23], which accounted for the uncertainty in haplotype reconstruction by
weight-adjusting each inferred haplotype according to its estimated posterior haplotype
probability. Associations between haplotype (0,1) and risk of incident CHD were also
evaluated by modeling each haplotype relative to all other haplotypes using Barlow’s method
[24]. The association analysis was repeated after excluding individuals with posterior
haplotype probabilities <0.75.
Gene–environment interaction testing was completed on a multiplicative scale between
selected CYP2J2 and CYP2C8 variants and baseline current smoking status (yes/no) using a
Wald χ2 test for significance of the estimated β-coefficient for the interaction term [26].
Because interaction hypothesis testing on a multiplicative scale is underpowered, the critical
value for statistical significance was set to α = 0.15, two-sided [27]. Stratified weighted
proportional hazards regression was also completed to explore further potential interactions.
To minimize the impact of the multiple statistical tests conducted in our analysis, we estimated
the false discovery rate (FDR) q-value of our findings, separately for CYP2J2 and CYP2C8,
which is defined as the expected proportion of statistical tests deemed significant that are
actually false positives (QVALUE) [28]. We considered statistical tests from the unadjusted,
model 1 and model 2 association analysis of each polymorphism and reconstructed haplotype
as independent, even though each model assessed the same independent variable and certain
genotype and haplotype associations are not completely independent. Additional q-value
estimates were also calculated for the gene-smoking interaction analysis. Only q-values for
significant findings are presented.
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Significant baseline differences in various risk factors were observed between incident CHD
cases and noncases included in the cohort random sample, as described previously [19,20].
Participants were significantly older and more likely to be male, cigarette smokers, diabetic,
hypertensive, and have abnormal fasting lipid panels compared with noncases.
CYP2J2/CYP2C8 genotype
The observed race-specific allele frequencies of the 10 CYP2J2 polymorphisms are presented
in Fig. 1. The R158C (CYP2J2*3), I192N (CYP2J2*4), and N404Y (CYP2J2*6)
polymorphisms were monomorphic in both Caucasians and African-Americans. Significant
LD was observed between certain CYP2J2 polymorphisms, particularly in Caucasians (Fig.
2). The minor allele frequencies of the I264M (0.041 versus 0.011), I269F (0.002 versus 0.141),
and K399R (0.108 versus 0.019) polymorphisms in CYP2C8 were significantly different in
Caucasians and African-Americans, respectively, in the cohort random sample (P<0.001 for
each comparison). Significant LD was not observed in either racial group (r2<0.01). The
distribution of all evaluated polymorphisms were in Hardy–Weinberg equilibrium in both
Caucasians and African-Americans (P>0.05).
CYP2J2 polymorphisms and coronary heart disease risk
In African-Americans, the variant – 50T allele was significantly less common among CHD
cases compared with cohort random sample noncases (20.9 versus 29.3%, respectively, P =
0.043) (Table 1). Moreover, presence of at least one variant – 50T allele was associated with
significantly lower risk of incident CHD events relative to – 50G homozygotes (model 2, HRR
0.58, 95% CI 0.35– 0.96, P = 0.036, q = 0.051) (Table 2). In Caucasians, no significant
difference in G-50T genotype frequency was observed across CHD case status (P = 0.719)
(Table 1), and no significant association between presence of the variant – 50T allele and CHD
risk was observed (model 2, HRR 1.15, 95% CI 0.78–1.70, P = 0.472) (Table 2). The rare
R49S variant allele appeared to be less common in CHD cases compared with noncases in
African-Americans (0.5 versus 2.5%, respectively) and Caucasians (0.1 versus 0.6%,
respectively) (Table 1).
Haplotype reconstruction identified five common haplotypes in African-Americans and three
in Caucasians, which accounted for 94.7 and 98.1% of all haplotypes, respectively. In African-
Americans, the overall haplotype distribution tended to be different in individuals with and
without CHD (P = 0.086); however, this difference was not statistically significant (Table 3).
No difference in haplotype distribution was observed in Caucasians (P = 0.731) (Table 3). In
African-Americans, haplotype TGTA (tagged by the polymorphism 1 (G-50T), seven and nine
variant alleles) was less frequent (8.1 versus 12.3%, P = 0.052) in CHD cases compared with
noncases, respectively (Table 3). Similar differences in haplotype TGTA frequency were also
observed using the expectation–maximization algorithm (P = 0.027). Moreover, presence of
at least one haplotype TGTA copy was significantly less common in CHD cases compared with
noncases (14.5 versus 22.9%, respectively, P = 0.027), and was associated with significantly
lower risk of incident CHD (model 2, HRR 0.51, 95% CI 0.29–0.91, P = 0.023, q = 0.041)
(Table 3). Significant associations were also observed after excluding the 1.5% of individuals
with a posterior haplotype probability <0.75 from the analysis (P = 0.020). In Caucasians,
presence of haplotype TG (tagged by the polymorphism 1 (G-50T) and seven variant alleles)
was not significantly associated with risk of incident CHD after covariate adjustment (model
2, HRR 1.33, 95% CI 0.87–2.02, P = 0.184) (Table 3).
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CYP2C8 polymorphisms and coronary heart disease risk
No significant differences in the genotype frequency of the I264M, I269F or K399R
polymorphisms in CYP2C8 were observed across CHD case status in either African-Americans
or Caucasians (Table 1). Moreover, presence of the I264M, I269F, or K399R variant alleles
were not significantly associated with risk of incident CHD after covariate adjustment (Table
2).
Genotype by smoking interaction
In Caucasians, cigarette smoking status at baseline appeared to modify the association between
CHD risk and both the I264M (P for interaction = 0.104, q = 0.166) and K399R (P for interaction
= 0.060, q = 0.160) polymorphisms in CYP2C8 (Table 4). A significant interaction was
identified when individuals carrying at least one variant allele in either the I264M or K399R
polymorphisms were compared with those wild-type for both (P for interaction = 0.008, q =
0.064) (Table 4). When stratified by smoking status, smokers carrying at least one variant allele
were at significantly higher risk of CHD compared with smokers wild type at both loci (model
2, HRR 1.89, 95% CI 1.05–3.38, P = 0.033). Smoking status did not modify risk associated
with the CYP2C8 variant I269F allele in African-Americans (P for interaction = 0.746), or the
CYP2J2 variant – 50T allele in either African-Americans (P for interaction = 0.605) or
Caucasians (P for interaction = 0.690).
Discussion
Our analysis demonstrated a statistically significant association between the variant – 50T allele
in CYP2J2 and lower risk of incident CHD events in African-Americans enrolled in the ARIC
study. A common CYP2J2 haplotype that carried the – 50T allele was also associated with
significantly lower CHD risk in African-Americans. The I264M, I269F, and K399R
polymorphisms in CYP2C8 were not associated with risk of CHD in either racial group. In
Caucasians, however, cigarette smokers carrying either the variant I264M or K399R allele were
at significantly higher risk of incident CHD.
P450 epoxygenase pathway
Endothelial dysfunction is associated with increased risk of acute cardiovascular events [2],
and is typically manifested by impairment in endothelial-dependent vasodilation [3]. The
vasodilatory and antiinflammatory properties of CYP2J2 and CYP2C8-derived EETs are
important mediators of this process [4,29]. Soluble epoxide hydrolase (EPHX2) rapidly
hydrolyzes EETs and is integrally involved in regulation of their cellular levels and vascular
effects [30]. We recently reported that the K55R variant allele in EPHX2 was associated with
significantly higher soluble epoxide hydrolase activity in vivo and higher risk of incident CHD
events in Caucasians [20]. Although regulation of EET levels by soluble epoxide hydrolase in
vivo is well documented, variation in CYP2J2 and/or CYP2C8-mediated EET biosynthesis
may also be critical. The relative contribution of each P450 epoxygenase to the regulation of
cellular and systemic EET levels, however, has not been extensively characterized, particularly
in humans.
CYP2J2 polymorphisms
The R158C, I192N, and N404Y polymorphisms possess significantly lower CYP2J2-mediated
epoxygenase activity in vitro [11]. These variants are, however, extremely infrequent and were
found to be monomorphic in the 2065 individuals genotyped in our analysis. The G-50T
polymorphism disrupts a Sp1 transcription factor binding site in the proximal promoter, leads
to reduced CYP2J2 transcription in vitro and represents the only common, functionally relevant
polymorphism in CYP2J2 identified to date [12]. The variant – 50T allele was associated with
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significantly lower plasma dihydroxyeicosatrienoic acid (DHET) levels and higher risk of
prevalent angiographically documented CHD in a recently characterized German population
[12]. In our analysis, the variant – 50T allele was, associated with significantly lower risk of
incident CHD clinical events in African-Americans at both the polymorphism and haplotype
levels, in contrast to these previous findings and our current hypotheses related to the beneficial
effects of EETs in the vasculature. The rare R49S variant allele also appeared to be less frequent
in Caucasian and African-American CHD cases; however, the metabolic relevance of this
infrequent variant has not been characterized. Interestingly, we recently reported an association
between the – 50T allele and lower risk of prevalent hypertension in Caucasians from a
Vanderbilt University cohort [31]. The – 50T allele was not significantly associated with risk
of incident CHD events in Caucasians from the ARIC study, inconsistent with the previously
described German population [12]. The primary analysis of this investigation by Spiecker et
al. [12], defined CHD angiographically, not by clinical event incidence as defined in the ARIC
study. A relationship between the – 50T allele and risk of prevalent acute coronary syndrome
events (adjusted odds ratio 1.38, 95% CI 0.85–2.25, P=0.19), which was similar to the
relationship we observed was also reported in Caucasians between a common haplotype
carrying the – 50T allele and risk of incident CHD events in the ARIC study (HRR 1.33, 95%
CI 0.87–2.02, P=0.184); however, neither relationship was statistically significant.
The relationship between the G-50T polymorphism and CHD risk appears to differ across the
Caucasian and African-American subsets of the ARIC cohort. In particular, the statistically
significant association observed in African-Americans existed in the opposite direction of both
preclinical findings and previous genetic epidemiological data in a Caucasian population
[12]. Additional metabolic studies evaluating the influence of the G-50T polymorphism on
EET biosynthesis in both Caucasians and African-Americans will be necessary to confirm the
functional relevance of this polymorphism in vivo. Significant associations, however, between
variants in other important endothelial genes (EPHX2, NOS3, ALOX5) and cardiovascular
disease risk have been reported in contrast to established hypotheses [32–34]. Although the
mechanism underlying the association between the – 50T allele and lower CHD risk in African-
Americans remains unclear, these data suggest that reduced P450-mediated EET biosynthesis
could have protective effects against the development of CHD clinical events. Despite their
well-characterized vasodilatory and antiinflammatory effects, preclinical evidence has
demonstrated that increased EET generation also significantly increases matrix
metalloproteinase (MMP) enzyme activity in endothelial cells [35]. The MMPs are potent
stimulators of vascular remodeling and atherosclerotic plaque destabilization, and are
integrally involved in the precipitation of plaque rupture and acute CHD events [36,37].
Perhaps the role of EET-mediated regulation of MMP activity is particularly important in
certain populations and genetic determinants of reduced EET generation, such as the G-50T
polymorphism in CYP2J2, can significantly reduce the risk of experiencing an acute CHD
clinical event via its downregulation of MMP activity. Interestingly, racial differences in
endothelial-mediated vasodilatory responses are well documented, with African-American
populations typically demonstrating more pronounced endothelial dysfunction compared with
Caucasian populations [38]. Enhanced impairment in endothelial nitric oxide synthase-
mediated nitric oxide biosynthesis has been implicated as one potential mechanism [39].
Potential population-specific differences in P450 epoxygenase-derived EET biosynthesis and
its effect on endothelial function, vascular inflammation, and MMP activity in humans remain
to be evaluated.
CYP2C8 polymorphisms
The I264M (*4), I269F (*2), and R139K/K399R (*3) polymorphisms possess significantly
lower CYP2C8 metabolic activity in vitro; however, only the R139K/K399R variant has been
associated with significantly reduced CYP2C8-mediated EET biosynthesis [13,14] and higher
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risk of prevalent myocardial infarction in a Swedish cohort [15]. The I264M and R139K/
K399R polymorphisms are more frequent in Caucasians, whereas the I269F polymorphism is
more frequent in African-Americans. Overall, these variants were not significantly associated
with risk of incident CHD events in the ARIC population. Similarly, we previously observed
no association between the R139K/K399R variant and risk of prevalent hypertension in a cohort
from Vanderbilt University [31]. In Caucasians, however, cigarette smoking history
significantly modified the association between the variant I264M and K399R alleles and CHD
incidence, such that smokers carrying either of these variant alleles were at the greatest risk of
developing CHD. Smoking did not modify the association between the G-50T polymorphism
in CYP2J2 and CHD risk, suggesting such an interaction may be isolated to CYP2C8-mediated
epoxygenase activity. Cigarette smoking is a well-characterized environmental risk factor that
substantially impairs endothelial function [3]. We have reported previously that cigarette
smoking modifies the association between each of the endothelial nitric oxide synthase
(NOS3) E298D and EPHX2 K55R polymorphisms and risk of incident CHD in Caucasians,
with the highest risk observed in smokers carrying these variant alleles [19,20]. Perhaps the
presence of established underlying endothelial dysfunction, as observed in cigarette smokers,
may be necessary for genetic variation in CYP2C8, NOS3, and EPHX2 to influence
significantly endothelial function and cardiovascular disease risk. Future studies will be
required to further characterize this potential gene–environment interaction and the
mechanistic influence of cigarette smoking on P450-mediated EET biosynthesis.
Limitations
First, although we are unable to elucidate mechanisms underlying the observed race-specific
associations, additional genetic and/or environmental factors not accounted for in our analysis
could be contributing to population differences in the likely complex relationship between the
P450 epoxygenase pathway, endothelial function, and cardiovascular disease risk. The
potential contribution of population stratification was not quantified or adjusted for in our
analysis. Consequently, all analyses were stratified by self-reported race, and comparison of
gene–disease associations across the Caucasian and African-American subsets of the ARIC
population should be interpreted with caution. Second, therapeutic interventions initiated
throughout follow-up could have impacted the observed relationships between CYP2J2 and
CYP2C8 polymorphisms and CHD risk. Inclusion of variables reflecting treatment with blood
pressure-lowering medications, cholesterol lowering medications or aspirin at baseline into
our modeling did not significantly alter any of the reported associations. For instance, the risk
of CHD associated with the CYP2J2 – 50T variant allele in African-Americans (adjusted HRR
0.50, 95% CI 0.30–0.84, P=0.009) and the reported interaction between the CYP2C8 I264M
and K399R variant alleles and cigarette smoking (P for interaction=0.003) remained
statistically significant when including these treatment variables in the model. Third, because
haplotypes are inferred, some uncertainty exists in the CYP2J2 haplotype assigned to each
individual. Similar results were, observed using the expectation–maximization algorithm and
after excluding individuals with posterior haplotype probabilities <0.75. Fourth, although we
specifically selected polymorphisms with known functional relevance and/or haplotype
tagging properties and utilized a hypothesis-driven approach in our analysis, we also
acknowledge it may be difficult to gauge the statistical significance of these findings
considering the number of comparisons completed. Consequently, we assessed the FDR across
all completed tests in our genotype and haplotype association analysis. Since all q-values
related to the association between CHD risk and both the G-50T polymorphism and TGTA
haplotype in African-Americans were estimated to be 0.051 or less, we have a high level of
confidence in these findings. Similarly, the FDR analysis enhanced our confidence in the
CYP2C8–smoking interaction findings. Our observations of significant gene–smoking
interactions with the I264M and K399R polymorphisms in CYP2C8 in the absence of
significant main effects, however, suggest these findings should be interpreted with caution.
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Genetic variation in CYP2J2 and CYP2C8 may be important risk factors for the development
of CHD clinical events. Future studies across multiple populations will undoubtedly be
required to validate our findings, in addition to molecular and physiological studies evaluating
the mechanistic relationship between the P450 epoxygenase pathway, endothelial function,
and cardiovascular disease risk.
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Nucleotide positions of the 10 CYP2J2 polymorphisms evaluated are given relative to the
CYP2J2 transcriptional start site (Genbank accession number AF272142). Activity is reported
as lower (↓) or unknown (?) relative to wild-type enzyme based on previous studies [11,12].
Cohort random sample minor allele frequencies are presented separately by race, and P-values
for the comparison of allele frequency across race by χ2 are reported. N/A, not applicable.
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Pairwise estimates of linkage disequilibrium (LD) between each CYP2J2 polymorphism are
plotted for (a) Caucasians and (b) African-Americans in the cohort random sample using
Haploview 3.2. Each polymorphism is numbered according to its position in the CYP2J2 gene
as presented in Fig. 1. Black squares indicate perfect LD (r2 = 1.0), white squares indicate zero
LD (r2 = 0.0), and increasing intensity of grey indicates increasing degrees of LD.
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Table 4
Gene–environment interaction between CYP2C8 polymorphisms, cigarette smoking and risk of incident CHD
in Caucasians
Smoking exposure CYP2C8 genotype Interaction P-value
I264M (CYP2C8*4) C/C C/G + G/G
Noncurrent smokers n = 477/400a n = 47/34a
 Model 1b 1 (referent) 1.13 (0.70–1.83)
 Model 2c 1 (referent) 0.72 (0.36–1.45)
Current smokers n = 219/111a n = 30/10a
 Model 1b 1.74 (1.32–2.31) 3.18 (1.47–6.90) 1.61 (0.64–4.09) 0.314
 Model 2c 1.62 (1.18–2.21) 2.76 (1.28–5.95) 2.38 (0.84–6.78) 0.104
K399R (CYP2C8*3) A/A A/G + G/G
Noncurrent smokers n = 422/362a n = 100/93a
 Model 1b 1 (referent) 0.87 (0.62–1.20)
 Model 2c 1 (referent) 0.79 (0.53–1.16)
Current smokers n = 196/99a n = 55/23a
 Model 1b 1.75 (1.30–2.36) 2.73 (1.58–4.75) 1.80 (0.91–3.54) 0.089
 Model 2c 1.64 (1.18–2.29) 2.63 (1.46–4.74) 2.03 (0.97–4.25) 0.060
I264M or K399Rd Wild-type Variant
Noncurrent smokers n = 383/330a n = 139/125a
 Model 1b 1 (referent) 0.90 (0.67–1.21)
 Model 2c 1 (referent) 0.73 (0.51–1.05)
Current smokers n = 169/90a n = 82/32a
 Model 1b 1.63 (1.19–2.24) 2.88 (1.80–4.62) 1.97 (1.08–3.61) 0.028
 Model 2c 1.48 (1.04–2.11) 2.65 (1.61–4.39) 2.45 (1.26–4.75) 0.008
Data presented as hazard rate ratio (95% confidence interval).
a
Number of CHD cases/noncases in each cell.
b
Adjusted for age, sex, and study center.
c
Adjusted for age, sex, study center, diabetes, hypertension, high-density lipoprotein cholesterol, total cholesterol, and body mass index.
d
Individuals carrying at least one variant allele for either the I264M (C/G + G/G) or K399R (A/G + G/G) polymorphism were compared with those wild-
type for both (C/C and A/A, respectively).
CHD, coronary heart disease.
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